We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Hepatitis B precore protein: pathogenic potential and therapeutic promise.
- Authors
Walsh, Renae; Locarnini, Stephen
- Abstract
Hepatitis B virus (HBV), a small and economically packaged double-stranded DNA virus, represents an enormous global health care burden. In spite of an effective vaccine, HBV is endemic in many countries. Chronic hepatitis B (CHB) results in the development of significant clinical outcomes such as liver disease and hepatocellular carcinoma (HCC), which are associated with high mortality rates. HBV is a non-cytopathic virus, with the host's immune response responsible for the associated liver damage. Indeed, HBV appears to be a master of manipulating and modulating the immune response to achieve persistent and chronic infection. The HBV precore protein or hepatitis B e antigen (HBeAg) is a key viral protein involved in these processes, for instance though the down-regulation of the innate immune response. The development of new therapies that target viral proteins, such as HBeAg, which regulates of the immune system, may offer a new wave of potential therapeutics to circumvent progression to CHB and liver disease.
- Publication
Yonsei medical journal, 2012, Vol 53, Issue 5, p875
- ISSN
1976-2437
- Publication type
Journal Article
- DOI
10.3349/ymj.2012.53.5.875